DOSSIER · 13F Holders · Q2 2026
GALT
GALECTIN THERAPEUTICS INC
107 institutions still hold GALECTIN THERAPEUTICS INC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
CUSIP 363225202·107 13F holders·last filed Jun 30, 2026
AI Holders Summary · Q2 2026
Galectin Therapeutics Inc. (GALT, CUSIP 363225202) appears in the 13F watch queue with reported institutional value below the $1M resolution floor, making substantive analysis currently unavailable. 94 holders reported suggests concentrated early-stage coverage from biotech-conviction managers rather than broad institutional adoption. Advise: treat as data-stub until next-quarter filing accumulation produces readable flows.
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.
Page 1 of 6
87 more holders available. Log in →